Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024.

Orginal from: Qiagen ¡¤ Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57 ¡¤ Net sales of $502 millio..

CareDx, Inc. (Nasdaq: CDNA) ¨C today announced financial results for the third quarter ended September 30, 2024.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Meningitis/Encephalitis Panel for clinical use.

Mindary Q3 Report: Operating Income Reaches ¥29.48 Billion Mindary has released its Q3 2024 results, revealing strong performance in the first three quarters of the year. The company ..

Original from: Revvity ¡¤ Revenue of $684 million; 2% reported growth; 2% organic growth ¡¤ GAAP EPS of $0.77; Adjusted EPS from continuing operations of $1.28 ¡¤ Raises full year 2024 adjust..

Original from: Illumina ¡¤ Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis ¡¤ Core Illumina GAAP operating margin of 68.6% and non-GAAP oper..

Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, announced new data demonstrating that the company¡¯s blood-biomarker alpha synuclein (¦Á-synuclein) signatures accurately detect the aggregation of ¦Á-synuclein in the brain from a simple blood draw. Results from the study, which will be shared in a poster presentation (#116) on October 31 at the Clinical Trials on Alzheimer¡¯s Disease (CTAD) international conference, demonstrate that Sunbird¡¯s technology could provide blood-based diagnosis of multiple neurodegenerative diseases, including Parkinson¡¯s disease, with high accuracy.

As part of ongoing efforts to enhance quality-assured testing options, the World Health Organization (WHO) has listed two additional mpox in vitro diagnostics under its Emergency Use Listing (EUL) procedure. WHO¡¯s EUL is based on the review of quality, safety and performance data in compliance with international standards while addressing the specific needs of low- and middle-income countries (LMICs).

Wolfe Research said Thursday that it has upgraded Danaher's shares to an Outperform rating from Peer Perform as the firm's growth is improving and it has capital to deploy.

Original from: Merck ¡¤ Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 7% - KEYTRUDA Sales Grew 17% to ..

Original from: bioM¨¦rieux ¡¤ +10.3% sales organic growth in the first nine months of the year with sales reaching €2,871m. A strong momentum fueled by the four growth drivers of the GO•28 strateg..

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024.

Original from: QIAGEN ¡¤ QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions ¡¤ Wit..

The US Administration for Strategic Response and Preparedness' Biomedical Advanced Research and Development Authority (BARDA) announced Monday that it has awarded a $9.2 million contract to Revvity to develop a home-use test for the detection of SARS-CoV-2 and influenza A and B.